How to Get Lantus (Insulin Glargine) in Iowa

What Lantus Is and Why Prescribers Choose It

Lantus is a long-acting basal insulin analogue delivering insulin glargine 100 units/mL with an onset of 1-2 hours, no pronounced peak, and a duration of approximately 24 hours. Its flat pharmacokinetic profile reduces nocturnal hypoglycemia risk compared with NPH insulin, a finding confirmed in multiple head-to-head trials. The ORIGIN trial (N=12,537, median follow-up 6.2 years) demonstrated that basal insulin glargine targeting fasting plasma glucose of 95 mg/dL or below did not increase cardiovascular events versus standard care in people with dysglycemia, and reduced incident type 2 diabetes by 28% in the prediabetes subgroup [1].

The FDA approved insulin glargine (Lantus) in April 2000 for adults with type 1 or type 2 diabetes requiring basal insulin coverage [2]. The American Diabetes Association's Standards of Care in Diabetes 2024 lists basal insulin analogues such as glargine as preferred over NPH when hypoglycemia risk is a clinical concern, citing reduced nocturnal events [3]. The Endocrine Society's 2022 clinical practice guideline on diabetes pharmacotherapy similarly identifies glargine-class insulins as first-line long-acting options for most adult patients initiating basal therapy [4].

Iowa prescribers favor Lantus and its biosimilar equivalents for both type 1 and type 2 diabetes. Type 1 patients typically pair it with a rapid-acting insulin at meals; type 2 patients may use it as monotherapy alongside oral agents.

Who Can Prescribe Lantus in Iowa

Any Iowa-licensed prescriber with authority to write Schedule II-exempt medications can prescribe Lantus. That includes MDs, DOs, nurse practitioners (NPs) holding an Advanced Registered Nurse Practitioner (ARNP) license under Iowa Code Chapter 152, and physician assistants (PAs) under Iowa Code Chapter 148C. Iowa ARNPs with full practice authority may prescribe without a physician collaboration agreement, which broadens telehealth prescribing capacity considerably [5].

Endocrinologists, primary care physicians, and internal medicine physicians routinely initiate and manage basal insulin therapy. Family nurse practitioners and certified diabetes care and education specialists (CDCESs) can also adjust doses in collaborative practice settings. There is no Iowa-specific restriction limiting Lantus prescribing to any one specialty.

For telehealth encounters, the Iowa Board of Medicine requires that a valid patient-provider relationship be established before controlled substances are prescribed, but insulin glargine is not a controlled substance. Under Iowa telehealth law, a prescriber may conduct a synchronous audio-video encounter, establish the clinical relationship, and issue an electronic prescription for Lantus during that same visit [6]. Some platforms offer asynchronous intake with prescriber review within a few hours, though synchronous visits provide the clearest legal footing under current Iowa Board guidance.

How to Get a Lantus Prescription in Iowa: Step-by-Step

Getting Lantus in Iowa follows a predictable pathway regardless of whether you use in-person or telehealth care.

Step 1. Confirm your diagnosis is documented. Iowa prescribers need a diagnosis code (E10.x for type 1, E11.x for type 2) before writing the prescription. If you are newly diagnosed, the prescriber will order fasting plasma glucose, HbA1c, and a C-peptide or fasting insulin level to characterize diabetes type. If you have an established diagnosis, bring prior records or authorize their transfer.

Step 2. Complete a clinical encounter. An in-person visit at an Iowa endocrinology clinic or primary care practice averages 30-45 minutes for a new diabetes patient. A telehealth visit on platforms licensed in Iowa averages 20-30 minutes. The clinician will assess weight, review current medications, check renal function (eGFR), and calculate a starting dose. The standard starting dose in type 2 diabetes is 0.1-0.2 units/kg/day or 10 units once nightly per ADA guidance [3].

Step 3. Receive and fill the prescription. Iowa pharmacies, including Hy-Vee Pharmacy, Walgreens, CVS, and Costco, all stock Lantus SoloSTAR pens and 10 mL vials. Mail-order options through Express Scripts and OptumRx also ship to Iowa addresses. A 90-day supply via mail-order often costs less out-of-pocket than three sequential 30-day retail fills.

Step 4. Enroll in Sanofi's Insulins Valyou Savings Program if cost is a barrier. Uninsured or underinsured Iowa patients may pay as little as $99/month for a 30-day supply through this manufacturer program. Sanofi's patient assistance program offers free insulin to qualifying low-income individuals [7].

Labs Needed Before Starting Lantus in Iowa

A prescriber cannot safely initiate basal insulin without a minimum laboratory panel. Required tests generally include HbA1c, fasting plasma glucose, comprehensive metabolic panel (CMP), and a urinalysis with microalbumin-to-creatinine ratio. These establish baseline glycemic control, confirm renal and hepatic function, and screen for existing diabetic nephropathy.

HbA1c directly guides the starting dose calculation. A patient presenting with HbA1c of 10% faces a higher insulin deficit than one at 7.5%, so the prescriber scales the initial dose accordingly. eGFR informs dosing because severe renal impairment (eGFR <30 mL/min/1.73 m²) slows insulin clearance and increases hypoglycemia risk, requiring a conservative start and more frequent titration checks [8].

C-peptide is not universally required for type 2 patients but is ordered when the clinical picture is ambiguous. A fasting C-peptide below 0.6 ng/mL in the presence of hyperglycemia strongly suggests type 1 or latent autoimmune diabetes in adults (LADA), which changes the prescribing strategy significantly [9].

Thyroid function (TSH) is frequently added at the first endocrinology visit because hypothyroidism worsens insulin resistance and can mimic poorly controlled diabetes. The ADA recommends screening for thyroid dysfunction in all patients with type 1 diabetes at diagnosis and periodically thereafter [3].

Telehealth platforms in Iowa typically require that labs drawn at a Quest Diagnostics or LabCorp patient service center within the prior 90 days are uploaded before the synchronous visit. If no recent labs exist, the prescriber may issue a lab order first, schedule the prescribing visit after results return, and provide dietary guidance in the interim.

Telehealth Prescribing of Lantus in Iowa

Iowa law explicitly permits telehealth prescribing of non-controlled medications after a valid clinical relationship is established. The Iowa Telehealth Act, codified in Iowa Code Section 135.192, requires that telehealth services meet the same standard of care as in-person services. Lantus qualifies for telehealth initiation because it is a non-controlled, FDA-approved medication with established dosing algorithms [6].

Several national telehealth platforms are licensed to prescribe in Iowa, including HealthRX, Teladoc Health, Hims/Hers (endocrinology arm), and Carbon Health. Iowa-specific direct primary care (DPC) practices also offer same-day or next-day telehealth slots for diabetes management.

A 2023 analysis in JAMA Internal Medicine found that telehealth-based diabetes management was associated with a 0.6% reduction in HbA1c at 12 months compared with usual care in rural populations, a group that includes a substantial share of Iowa's diabetes patients [10]. Iowa has 44 counties designated as primary care Health Professional Shortage Areas (HPSAs) by HRSA, making telehealth access particularly relevant for patients outside the Des Moines, Cedar Rapids, and Iowa City metro areas [11].

After a telehealth visit, the electronic prescription is transmitted directly to the patient's chosen Iowa pharmacy via Surescripts. Most retail pharmacies confirm receipt and dispense within 4-8 hours. Mail-order pharmacies take 3-7 business days for first fills.

Prior Authorization for Lantus in Iowa

Commercial insurance in Iowa frequently requires prior authorization (PA) for Lantus because it is a brand-name drug when biosimilar alternatives (Basaglar, Rezvoglar) are available at lower plan cost. Iowa Medicaid does not cover Lantus as of 2025, so PA on the Medicaid side is moot. For commercial plans, the PA process typically takes 3-10 business days if submitted correctly on the first attempt.

The standard PA documentation package for Lantus in Iowa includes:

• Diagnosis codes (ICD-10 E10.x or E11.x) with date of initial diagnosis
• Most recent HbA1c result with lab date
• Documentation of trial and failure or contraindication to at least one preferred formulary insulin (commonly NPH or the plan's preferred biosimilar glargine)
• Prescriber attestation that Lantus is medically necessary for the patient

The phrase "step therapy failure" is central to most Iowa commercial PA criteria. If a plan's formulary places Basaglar on Tier 2 and Lantus on Tier 4 with PA required, the prescriber must document that the patient either tried Basaglar and experienced inadequate control or a tolerability issue, or that a specific clinical reason supports skipping step therapy entirely [12].

The American Diabetes Association's position statement on insulin access states: "Prior authorization policies and step therapy requirements for insulin impose administrative burdens that delay care and contribute to adverse outcomes, including diabetic ketoacidosis and hospitalization." [13]. Iowa does not have a state law capping insulin out-of-pocket costs as of July 2025, unlike the federal $35/month cap that applies only to Medicare Part D beneficiaries under the Inflation Reduction Act [14].

For patients who cannot get PA approved, Basaglar (insulin glargine-aabc) and Rezvoglar (insulin glargine-aglr) are FDA-approved interchangeable biosimilars that deliver the same 24-hour flat-profile basal coverage as Lantus at meaningfully lower list prices [15].

Transferring a Lantus Prescription to Iowa

Patients relocating to Iowa or snowbirds maintaining residences in two states can transfer an existing Lantus prescription under Iowa pharmacy law, Iowa Administrative Code 657, Chapter 6. A prescription for a non-controlled substance may be transferred between pharmacies one time, or an unlimited number of times if both pharmacies share the same electronic database (common within large chain networks such as Walgreens or CVS).

To transfer, contact the receiving Iowa pharmacy by phone or app, provide the original pharmacy's name and phone number plus the prescription number, and the pharmacist will handle the transfer. The original prescriber does not need to be re-contacted unless the prescription has expired or the quantity needs adjustment.

If the original prescription was written by an out-of-state provider not licensed in Iowa, that prescription remains valid for its written quantity and refills but cannot be renewed by that provider in Iowa. At renewal, an Iowa-licensed prescriber (including one practicing telehealth from outside Iowa but licensed by the Iowa Medical Board) must issue a new prescription [5].

Patients with a continuous glucose monitor (CGM) or pump-integrated regimen should bring device download reports to the new Iowa prescriber. The ADA 2024 standards specify that CGM time-in-range data should be reviewed at every diabetes management encounter to guide basal insulin titration [3].

503A Compounding Pharmacies and Insulin Glargine in Iowa

Iowa-licensed 503A compounding pharmacies may compound insulin glargine preparations for individual patients, but they operate under significant regulatory constraints. The FDA does not place insulin glargine on its 503A bulks list of ingredients approved for compounding, which means a 503A pharmacy compounding glargine must rely on a valid patient-specific prescription and a clinical rationale for why the commercial product does not meet the patient's needs [16].

In practice, 503A compounding of insulin glargine in Iowa is rare and typically reserved for patients requiring a non-standard concentration, such as U-200 or U-500 preparations for highly insulin-resistant patients, or those with documented allergy to an excipient in the commercial formulation. The commercial Lantus SoloSTAR contains metacresol as a preservative; documented metacresol hypersensitivity is one legitimate rationale for a compounded glargine preparation.

Any Iowa patient considering a compounded insulin should verify that the pharmacy holds a current Iowa Board of Pharmacy 503A license. The Iowa Board of Pharmacy maintains a public licensee lookup at pharmacy.iowa.gov. Compounded insulins are not FDA-approved for potency or sterility in the same way as commercially manufactured vials, so they carry modestly different safety considerations [16].

Cost and Affordability in Iowa

Lantus list price at Iowa retail pharmacies runs approximately $300-$360 per 10 mL vial (100 units/mL) as of mid-2025, though actual out-of-pocket cost varies widely based on insurance tier, deductible stage, and pharmacy benefit structure. GoodRx coupons frequently reduce the retail price to $90-$130 per vial at Iowa pharmacies, including Hy-Vee and Costco.

Sanofi's Insulins Valyou Savings Program caps out-of-pocket cost at $99/month for all Sanofi insulins, including Lantus, for commercially insured and uninsured patients who enroll directly [7]. The program does not apply to government payers (Medicare, Medicaid, VA).

Basaglar (Eli Lilly) and Rezvoglar (Biocon) carry list prices roughly 65-80% lower than Lantus and are therapeutically interchangeable per the FDA's interchangeable biosimilar designation, meaning an Iowa pharmacist may substitute either for Lantus without contacting the prescriber unless the prescriber writes "brand medically necessary" [15]. For most patients, the clinical outcome on an interchangeable biosimilar glargine is identical to Lantus.

Iowa's Senior Living Trust Fund does not specifically cover outpatient insulin for non-Medicaid seniors, but the federal Extra Help (Low Income Subsidy) program caps insulin costs at $35/month for Medicare Part D enrollees. Iowa SHIP counselors at 1-800-351-4664 can assist with enrollment.

Titrating Your Lantus Dose After You Start

Starting is only the first step. The ADA recommends a "treat-to-target" titration protocol for basal insulin: increase the dose by 2 units every 3 days until fasting glucose consistently falls in the target range of 80-130 mg/dL [3]. A large titration trial (Treat-to-Target, N=756) demonstrated that algorithm-driven self-titration of glargine achieved HbA1c below 7% in 58% of type 2 patients at 24 weeks without significant hypoglycemia [17].

Your Iowa prescriber should schedule a follow-up encounter (telehealth or in-person) at 4-6 weeks after initiation to review fasting glucose logs, evaluate for nocturnal hypoglycemia, and adjust the dose. At 3 months, a repeat HbA1c confirms whether the basal regimen alone achieves target or whether bolus insulin or a GLP-1 receptor agonist should be added.

Hypoglycemia (blood glucose <70 mg/dL) is the primary safety concern with Lantus dose escalation. Patients should have rapid-acting glucose (15-20 g of glucose tablets or juice) on hand before starting any basal insulin. Severe hypoglycemia requiring third-party assistance occurred in 2.7% of glargine-treated patients versus 3.7% of NPH-treated patients over 52 weeks in one key registration trial [2]. Confirm your Iowa prescriber has documented a hypoglycemia management plan in your chart before your first injection.